For the tratamiencombinaciones inmunoterapu00c9uticas inmunoterapu00c9uticas combinations for the treatment of tumors that over Express gangliu00d3sidos to tumors that over Express gangliu00d3sidos

摘要

The present Invention relates to the field of Biotechnology and more specifically with the obtaining of New Antibodies using recombinant DNA Technology recombinBefore.The object of the present Invention is to obtain Monoclonal Antibodies (MABS) less immunogenic and retain ligand binding Affinity.For Therapeutic use in humans.The essence of the invention lies in obtaining modified Antibodies.The Modifications are performed by Genetic Engineering on sequences of the murine monoclonal antibody (MAB P3, P3)Produced by the hybridoma deposited under the Budapest Treaty on the 94113026 ECACC and number of anti Idiotype Monoclonal Antibody (acmai Tinv, ECACC 97112901, Tinv)With the aim of obtaining a modified Antibody with the same Antibody Recognition Properties of original and less immunogenic when administered to patients.Modified Antibodies described in this Invention are Chimeric; contain the variable domains of murine Immunoglobulin and the constant regions of inmunoglobuLina Human and Humanized Antibodies.In addition to containing the constant regions of human immunoglobulin have been specifically modified in the region of murine Frameworks (FRS) and within these, in those areas that canResult in antigenic site for T cells, so that there are some FRS positions that are Human.